L&T Energy GreenTech to set up India's largest green hydrogen plant for Indian Oil refinery
green hydrogen plant
at
Indian Oil Corporation Ltd
's (
IOCL
) Panipat Refinery in Haryana, the company announced on Monday.
The plant will operate 24/7 using
renewable energy
, supporting IOCS's strategy to decarbonise its refining operations and contribute to country's net-zero ambitions.
Explore courses from Top Institutes in
Select a Course Category
Others
Product Management
Data Science
PGDM
Project Management
Management
Digital Marketing
Design Thinking
Operations Management
Degree
others
MBA
Finance
Artificial Intelligence
Public Policy
Data Science
healthcare
MCA
Healthcare
Cybersecurity
Data Analytics
CXO
Leadership
Skills you'll gain:
Duration:
7 Months
S P Jain Institute of Management and Research
CERT-SPJIMR Exec Cert Prog in AI for Biz India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
16 Weeks
Indian School of Business
CERT-ISB Transforming HR with Analytics & AI India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
9 months
IIM Lucknow
SEPO - IIML CHRO India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
28 Weeks
MICA
CERT-MICA SBMPR Async India
Starts on
undefined
Get Details
The
green hydrogen
plant will be developed on a build-own-operate (BOO) basis. It will supply 10,000 tonnes of green hydrogen annually to IOCL for 25 years, supporting Government of India's National Green Hydrogen Mission.
The plant will produce green hydrogen using high-pressure alkaline electrolysers manufactured at L&T Electrolysers Ltd's facility in Hazira, Gujarat, as per company release.
Live Events
The initiative marks a significant milestone in India's energy transition and reinforces L&T's leadership in delivering sustainable, scalable clean energy infrastructure, the company said.
'The decision to set up India's maiden green hydrogen plant validates our strategy to lead the nation's energy transition. This long-term project not only deepens our partnership with IOCL but also reinforces our capability to deliver large-scale clean energy solutions. As a first mover in India's green hydrogen space, we are proud to lay the foundation for cleaner industrial processes at scale," said Subramaniam Sarma, Deputy Managing Director & President, L&T.
"This project reflects our end-to-end green energy capabilities — from electrolyser manufacturing to execution and operation," Derek Shah, Head – Green Manufacturing & Development, L&T added.
LTEG is a wholly-owned subsidiary of Larsen & Toubro (L&T).
Shares of Larsen & Toubro Ltd. were trading at Rs 3490.80 per unit with an increase of 0.77% on BSE at 10:52 AM on Monday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
9 minutes ago
- India.com
India's Pharma Exports Have Shot Up By 92% In Last 6 Years: Minister
New Delhi: Various schemes being implemented by the Centre to realise the vision of Aatmanirbhar Bharat in the pharmaceutical sector have resulted in India's exports of drugs and pharmaceuticals increasing by 92 per cent, from Rs 1,28,028 crore in FY2018-19 to Rs 2,45,962 crore in FY2024-25, the Parliament was informed on Friday. The schemes include the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme, the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, the PLI Scheme for Bulk Drugs, Scheme for Promotion of Bulk Drug Parks, and Strengthening of Pharmaceutical Industry scheme, Minister of State for Chemicals and Fertilisers Anupriya Patel told the Lok Sabha in a written reply to a question. The PRIP scheme has been launched with an outlay of Rs 5,000 crore to transform India's Pharma MedTech sector from cost- to innovation-based growth by strengthening research and promoting industry-academia linkage for research and development in priority areas in drug discovery and development and medical devices. Under this scheme, seven Centres of Excellence (CoEs) have been set up, she said. The PLI Scheme for Pharmaceuticals aims to enhance India's manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high-value goods in the pharmaceutical sector. The minister said that the scheme has enabled enhanced investment and production in eligible products. As of March 2025, the committed investment of Rs 17,275 crore targeted over the six-year period of the scheme stands substantially exceeded with a cumulative investment of Rs 37,306 crore made by the scheme's third year, and cumulative sales of approved products of Rs 2,66,528 crore have been made, including exports of Rs 1,70,807 crore. The PLI Scheme for Bulk Drugs, which has a total budgetary outlay of Rs 6,940 crore, aims to avoid disruption in the supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs for which there are no alternatives by reducing supply disruption risk due to excessive dependence on a single source. As of March 2025, the committed investment of Rs 3,938.5 crore under projects approved under the scheme for investment over the six-year production period of the scheme stands substantially exceeded with a cumulative investment of Rs 4,570 crore made by the scheme's third year, she further stated. The minister also highlighted that the government launched the Pradhan Mantri Bhartiya Janaushadhi Pariyojana scheme to make quality generic medicines available at affordable prices to all. Under the scheme, dedicated outlets known as Jan Aushadhi Kendras (JAKs) are opened across the country to provide medicines at prices that are about 50 per cent to 80 per cent lower than those of leading branded medicines in the market. Till June 6, 2025, a total of 16,912 JAKs have been opened, and on average, about 10 to 12 lakh persons visit these Kendras daily and avail of quality medicines at affordable prices. As many as 2,110 medicines and 315 surgicals, medical consumables and devices are under the scheme product basket, covering all major therapeutic groups, such as cardiovascular, anti-cancer, anti-diabetic, anti-infectives, anti-allergic and gastro-intestinal medicines and nutraceuticals. As a result of the scheme, in the last 11 years, estimated savings of about Rs 38,000 crore have accrued to citizens in comparison to the prices of branded medicines. Further, the scheme has provided self-employment to over 16,000 persons, including over 6,800 women entrepreneurs, the minister added.
News18
17 minutes ago
- News18
Hyundai India Gets Rs 517.34 Cr Tax With Penalty Demand From GST Authority, Here's Why
Last Updated: The company said there is no impact on its financial, operational or other activities due to the order and is reviewing the order and will exercise the right to file an appeal. Hyundai Motor India Ltd on Tuesday said it has received a demand of Rs 517.34 crore from tax authorities, along with penalty, for alleged short payment of GST compensation cess on its certain SUV models. The company has received an order from Commissioner (Appeals), CGST Dept, Tamil Nadu, confirming GST compensation cess demand of Rs 258.67 crore, along with penalty of Rs 258.67 crore, on the allegation of short payment of GST compensation cess on certain SUV models for the period September 2017 – March 2020, Hyundai Motor India Ltd said in a regulatory filing. Reacting to the demand, a company spokesperson said, 'HMIL is of the view that the amendment and the clarifications given by the Central Board of Indirect Tax and Customs (CBIC) to resolve the issue faced by the industry on this matter are in favour of the company. We are in the process of reviewing the order and will exercise the right to seek a legal remedy through an appropriate forum." The company asserted that there is no impact on its financial, operational or other activities due to the order and is reviewing the order and will exercise the right to file an appeal. . view comments First Published: July 26, 2025, 08:17 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Time of India
21 minutes ago
- Time of India
Atal Pension Yojana enrolments cross 8 crore mark; adds 39 lakh new subscribers so far in FY26
Social Security scheme Atal Pension Yojana has crossed 8 crore total gross enrolments, with an addition of 39 lakh new subscribers so far in the current fiscal, the Finance Ministry said on Friday. APY was launched on May 9, 2015. Explore courses from Top Institutes in Please select course: Select a Course Category Technology others Digital Marketing MBA Operations Management Healthcare MCA healthcare Data Analytics Management Cybersecurity Finance Leadership Others Project Management PGDM Public Policy Data Science Artificial Intelligence CXO Design Thinking Product Management Degree Data Science Skills you'll gain: Duration: 12 Weeks MIT xPRO CERT-MIT XPRO Building AI Prod India Starts on undefined Get Details "The Atal Pension Yojana (APY), a flagship social security scheme of the Government of India administered by PFRDA , has achieved a significant milestone by surpassing 8 crore total gross enrolments with an addition of 39 lakh new subscribers in the current Financial Year (FY 2025-26) alone," the ministry said in a statement. Launched with a vision to create a universal social security system for all Indians, APY is a voluntary, contributory pension scheme , focused on the poor, the underprivileged, and workers in the unorganised sector. APY assures a guaranteed monthly pension of Rs 1,000 to Rs 5,000 for the subscriber post-60 years of age, the same pension to the spouse after the subscriber's demise, and return of the accumulated corpus to the nominee after the death of both. It is open to all Indian citizens between the age of 18-40 years, except those who are or have been income tax payers.
